Newsletter | November 13, 2026

11.13.26 -- Five Lessons For Biotech CEOs Pioneering A New Therapeutic Modality

FEATURED ARTICLE

Five Lessons For Biotech CEOs Pioneering A New Therapeutic Modality

Scientific conviction, resilience, and clinical evidence can turn early skepticism into meaningful progress for patients, writes RiboX Therapeutics' Weiyi Zhang, Ph.D.

INDUSTRY INSIGHTS

The Hidden Truths About Prepaid Cards In Clinical Trials

Prepaid debit cards have revolutionized participant payments in clinical trials. However, questions are being raised about transparency and who sets fees.

Yes, Your Study Is At Risk: Risk Mitigation Plans For Endpoints

Ocular endpoints often introduce unique bottlenecks that can stall enrollment and compromise data integrity. This presentation provides the tools for a streamlined, resilient clinical trial strategy.

Clinical Trial Evaluation And Referral Challenging For Physicians

Physicians often encounter information gaps when evaluating clinical trials for patients. A recent survey indicates a fragmented, confusing trial information landscape that is difficult to navigate.

The Innovations Shaping 2026 CNS Clinical Trials

Explore how AI, digital tools, and site‑centered design can reduce burden, strengthen data quality, and support more reliable trial execution.

A Hotbed For Life Sciences: A Unique Value Proposition

Learn about a hotbed for the life sciences, offering a deep talent pool, an extensive R&D presence, and dedicated backing by local government in the form of strategic investment.

What Everyone Needs To Know About Polymorphs

Build a strong foundation in solid form science — especially polymorphism — to reduce risk, control variability, and accelerate your path from development to reliable, cost-effective manufacturing.

Connect With Life Science Leader: